Clinical remission was achieved in 63.2% (12/19) of patients treated with MB310 versus 30.0% (3/10) on placebo in an ITT analysis of a 29‑patient Phase 1b study in mild-to-moderate ulcerative colitis. All MB310 patients who entered follow-up (n=12) remained in clinical remission with complete resolution of rectal bleeding at end of study. MB310 showed improvements in histological markers of mucosal damage and reductions in fecal calprotectin, with a safety profile indistinguishable from placebo. All eight strains in the consortium engrafted rapidly and were maintained through 12 weeks of dosing and 12 weeks of follow-up.
Microbiotica reported positive first-in-human results from COMPOSER-1, a randomized, double-blind, placebo-controlled trial conducted across five European countries. Patients received once-daily oral MB310 or matched placebo for 12 weeks on top of standard of care, with a 12-week post-dosing follow-up. The study met primary and secondary objectives of safety, tolerability, and engraftment, alongside statistically significant efficacy signals on clinical and objective measures. The company plans an adaptive Phase 2/3 program evaluating MB310 in combination with anti-inflammatory and/or immunomodulatory induction regimens.
The strategic throughline is a bid to reposition microbiome-based therapeutics in UC as disease-modifying maintenance adjuncts rather than stand-alone induction agents. By demonstrating durable engraftment of a defined eight-strain consortium and concordant signals across symptoms, histology, and biomarkers, Microbiotica is addressing two persistent weaknesses in the field: variable product composition and uncertain mechanism-to-outcome linkage. The intent to pair MB310 with faster-acting induction therapies acknowledges the likely slower onset of microbiome modulation while aiming to deliver longer-term remission without additional immunosuppression. That said, the dataset is small, leverages partial Mayo for remission, and includes background standard therapies, limiting interpretability versus modern endpoints emphasizing endoscopic and histologic remission and steroid-free status.
For sites, an oral LBP simplifies administration but adds operational layers: frequent stool sampling, centralized sequencing to confirm engraftment, and cold-chain handling for a live consortium. Low adverse event burden could reduce acute safety monitoring, but infection vigilance and antibiotic exposure tracking will be critical. Sponsors and CROs should expect complex protocol architecture in the next phase: stratification by baseline therapy and biologic experience, clear definitions around induction partners and timing, and pre-specified engraftment analyses as potential on-treatment biomarkers. Vendors supporting microbiome analytics, biobanking, and fecal calprotectin testing are positioned to benefit. Regulators will focus on CMC rigor for multi-strain LBPs, potency and release assays tied to mechanism, and alignment of primary endpoints with current UC guidance that prioritizes endoscopic and histologic outcomes and steroid-free remission.
The key watch items are the Phase 2/3 design choices and geographic scope, particularly whether the program aligns US and EU endpoints and standard-of-care backbones. Clarity on target population—bio-naïve versus bio-experienced, induction-dependent versus maintenance—will shape effect size expectations and operational complexity. Manufacturing scalability and lot-to-lot comparability for eight GMP strains remain nontrivial risks, as does the need to reproduce both efficacy and engraftment in a larger, more heterogeneous cohort. Drug–microbiome interactions with concomitant therapies and antibiotics will need proactive management. If the signal translates with stronger, endoscopy-anchored endpoints and durable benefit beyond six months, MB310 could emerge as a maintenance adjunct integrated into induction-to-maintenance pathways, potentially guided by engraftment as a real-time pharmacodynamic marker.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
